3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
The aims of the current study are1. to investigate the efficacy and safety of a continuous infusion of 'low dose' danaparoid in patients with acute renal failure needing CRRT2. to investigate whether repeated measurements of anti-Xa levels…
Approved WMORecruiting
Our objective is to study if reduced anticoagulation targets diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.